Safety Study of PTP-001 for Treating Knee Osteoarthritis
A Prospective, Open-Label, Dose-Escalation Phase 1 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- James R. Urbaniak, MD, Duke Sports Science Institute
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29406
- Coastal Carolina Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written consent to participate in the study
- Male or female, aged 40 to 80 years
- Symptomatic knee OA with Kellgren-Lawrence radiographic classification of 2 or 3
- Non-responsive after at least 3 months of conservative therapy for knee OA
- Females of childbearing potential must have negative pregnancy test result prior to treatment and must commit to highly effective methods of contraception for at least 6 months after treatment
- Willingness to report oral analgesic treatment used for knee pain and to discontinue analgesic treatment for knee pain in 24 hours prior to each study visit
- Willingness to limit use of pain rescue medication to oral acetaminophen for management of painful knee OA flare
Exclusion Criteria:
- Body mass index (BMI) ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with condition that warrants weight loss surgery
- Presence of active infection of index knee or systemic infection requiring treatment within 3 months of Screening
- Administration of IA injection within 3 months of Screening
- Significant acute injury to index knee within 3 months of Screening
- Surgery to index knee within 6 months of Screening or planned surgery to index knee within 6 months after Screening
- Unstable index knee joint
- History of radiation therapy of index knee
- Known vascular or neurological disorder affecting the index knee
- Osteonecrosis of either knee
- Clinical diagnosis of inflammatory arthritis
- Clinical diagnosis of autoimmune disease affecting the musculoskeletal system
- Use of any other investigational therapy within 3 months of Screening or planned for the duration of the study
- Current anti-coagulant use
- History of receiving a solid organ or hematologic transplant
- History of malignancy or radiotherapy within 5 years of Screening, except for basal or squamous cell carcinoma of the skin
- Use of immunosuppressive or chemotherapeutic agents within 5 years of Screening
- Known allergy to local anesthetics or allograft tissues
- Known history of hepatitis
- Known history of thrombotic or thromboembolic phenomena.
- Known history of primary or secondary immunodeficiency disorders
- Presence of concurrent medical condition that, in the investigator's judgement, could compromise participant safety or interfere with the required study assessments and study participation.
Note: Other protocol defined inclusion/exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: PTP-001 - Low Dose (100 mg)
intra-articular injection of 100 mg PTP-001 resuspended with 4 mL of normal saline
|
allogeneic placental tissue particulate
|
|
EXPERIMENTAL: PTP-001 - High Dose (200 mg)
intra-articular injection of 200 mg PTP-001 resuspended with 4 mL of normal saline
|
allogeneic placental tissue particulate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of local and systemic treatment emergent adverse events (AEs) and incidence of abnormal laboratory and immunogenicity panels
Time Frame: Baseline to Week 52
|
Incidence of local and systemic treatment emergent adverse events (AEs), including clinical laboratory and immunogenicity panels, after a single intra-articular injection of PTP-001.
|
Baseline to Week 52
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Western Ontario and McMaster University (WOMAC) Pain Responder Rate
Time Frame: Week 26 and Week 52
|
Week 26 and Week 52
|
|
|
WOMAC Physical Function Responder Rate
Time Frame: Week 26 and Week 52
|
Week 26 and Week 52
|
|
|
Change from baseline in pain of the index knee, by evaluating the WOMAC Pain subscale score (the possible total score ranging from 0-50 for pain)
Time Frame: Baseline to Week 52
|
WOMAC Numerical Rating Scale (NRS) 3.1 questionnaire is a health status measure questionnaire of 24 questions comprising 3 subscales (pain, stiffness and physical function).
WOMAC A (measure of pain) is measured on 11-point NRS ranging from 0 (none) to 10 (extreme), where higher score represents higher pain.
|
Baseline to Week 52
|
|
Change from baseline in physical function of the index knee, by evaluating the WOMAC Physical Function subscale score (the possible total score ranging from 0-170 for Physical Function)
Time Frame: Baseline to Week 52
|
WOMAC Numerical Rating Scale (NRS) 3.1 questionnaire is a health status measure questionnaire of 24 questions comprising 3 subscales (pain, stiffness and physical function).
WOMAC C (measure of physical function) is measured on 11-point NRS ranging from 0 (none) to 10 (extreme), where higher score represents higher pain.
|
Baseline to Week 52
|
|
Change from baseline in patient global assessment of OA, by assessing the participants assessment of how they are doing considering arthritis in index knee (the possible answers include "Very Good", "Good", "Acceptable", "Poor", "Very Poor"
Time Frame: Baseline to Week 52
|
Baseline to Week 52
|
|
|
Change from baseline in health-related quality of life, by assessing the items from the Short Form 36 (SF-36) survey
Time Frame: Baseline to Week 52
|
The SF-36 measures 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health (the possible total normalized score ranges from 0-100).
Higher scores on the SF-36 indicate better health status.
|
Baseline to Week 52
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in biochemical markers (CTX-II & PRO-C2)
Time Frame: Baseline to Week 52
|
|
Baseline to Week 52
|
|
Change from baseline in joint space width of the index knee, assessed radiographically (OARSI radiographic scoring)
Time Frame: Baseline to Week 52
|
Baseline to Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Annunziato Amendola, MD, James R. Urbaniak, MD, Duke Sports Science Institute
Publications and helpful links
General Publications
- Flannery CR, Seaman SA, Buddin KE, et al. Characterization and preclinical efficacy of PTP-001, a novel human tissue biologic in development for the treatment of OA. Osteoarthritis Cartilage. 2020 Apr;28(Supplement 1):S487-S489. doi: 10.1016/j.joca.2020.02.763
- Flannery CR, Seaman SA, Buddin KE, Nasert MA, Semler EJ, Kelley KL, Long M, Favret J, Pavesio A, Loeser RF. A novel placental tissue biologic, PTP-001, inhibits inflammatory and catabolic responses in vitro and prevents pain and cartilage degeneration in a rat model of osteoarthritis. Osteoarthritis Cartilage. 2021 Aug;29(8):1203-1212. doi: 10.1016/j.joca.2021.03.022. Epub 2021 May 20.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KOA-20-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.